Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 97

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 97
---
,000 | ) |     |            | (100.0 | )% |
| Interest income (expense), net                             |     |                           |      20,562 |   |     |                |     (22,188 | ) |     |            |      42,750 |   |     |            |  192.7 | %  |
| Total other income (expense), net                          |     |                           |  (1,342,740 | ) |     |                |   5,126,230 |   |     |            |  (6,468,970 | ) |     |            | (126.2 | )% |
| Net loss                                                   |     |                           | (15,379,641 | ) |     |                |  (8,976,315 | ) |     |            |  (6,403,326 | ) |     |            |   71.3 | %  |
| Deemed dividend on Series A, B and C Preferred Stock       |     |                           | (24,964,518 | ) |     |                |           - |   |     |            | (24,964,518 | ) |     |            |    100 | %  |
| Deemed dividend on Series D Preferred Stock                |     |                           |  (6,649,828 | ) |     |                |           - |   |     |            |  (6,649,828 | ) |     |            |    100 | %  |
| Deemed dividend related to Series C Common Warrants        |     |                           |     (84,083 | ) |     |                |           - |   |     |            |     (84,083 | ) |     |            |    100 | %  |
| Net loss attributable to common stockholders               |     | $                         | (47,078,070 | ) |     | $              |  (8,976,315 | ) |     | $          | (38,101,755 | ) |     |            |  424.5 | %  |

Research and Development Expenses

Research and development
expenses were $8,048,000 for the nine months ended September 30, 2025 as compared to $6,157,000 for the nine months ended September 30,
2024, reflecting an increase of $1,891,000. The increase was primarily attributable to an increase in clinical